aTyr Pharma Inc (NASDAQ: LIFE) — Perfil da empresa, notícias e dados financeiros
aTyr Pharma is a biotech firm focused on developing novel therapies for severe inflammatory diseases using immune modulation.
aTyr Pharma Inc
aTyr Pharma (NASDAQ:LIFE) is a biotech company focused on discovering and developing innovative medicines from its unique immune modulation platform. aTyr is traded on NASDAQ under the ticker symbol LIFE. The company’s key project is its lead therapeutic candidate, efzofitimod, aimed at treating various severe inflammatory diseases. By leveraging their proprietary biological pathways involving extracellular histidyl tRNA synthetase, aTyr is pushing the boundaries of targeting diseases with unmet medical needs. The main objective is to advance efzofitimod through clinical trials and eventually bring it to market, potentially offering new treatments for patients with serious conditions.
Resumo
Operações
Produtos e/ou serviços de aTyr Pharma Inc
- Efzofitimod: A clinical-stage immunomodulator primarily aimed at treating pulmonary sarcoidosis and other interstitial lung diseases.
- ATYR2810: An anti-Neuropilin-2 (NRP2) antibody under investigation, targeting solid tumor cancers.
- Research & Development: Focused on developing innovative therapeutics derived from its new class of biological modulators, the extracellular tRNA synthetase platform.
- Nrp2: Exploring NRP2 biology to understand its role in disease processes and developing targeted treatments.
- Preclinical Pipeline: Early-stage programs researching additional therapeutic candidates in immunology and fibrosis.
- Collaborations: Partnering with leading academic and industry institutions to advance therapeutic discoveries and expand potential indications.
equipe executiva do aTyr Pharma Inc
- Peter George ColisCo-Founder, CEO & Chair of Board of Directors
- Lingke WangCo-Founder, President & Director
- Vipul SharmaChief Technology Officer
- Kunal MehtaSenior Vice President of Finance
- Christopher Michael CapozziChief Financial Officer
- Brett WilsonSenior Vice President of Strategic Accounts & Operations
- Brandt Walter KucharskiChief Accounting Officer
- Aaron Ellison TurnerVice President of Investor Relations
- Porter NolanGeneral Counsel
- Laura HeegerChief Compliance & Privacy Officer
Principais indicadores financeiros
Resultados divulgados pela aTyr Pharma Inc, em USD.
- Cap. de mercado
- 2,8 bi
- Receita (TTM)
- 586,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.1
- Dividend yield
- —
- Margem de lucro
- -18.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 387,6 mi | 72,9 mi | 71,2 mi | |
| 254,9 mi | 48,7 mi | 48,8 mi | |
| 159,8 mi | -2,9 mi | 1,7 mi |